Article

Updates in ALK-Positive Non–Small Cell Lung Cancer

On May 4, 2021, a select group of oncologists participated in a virtual workshop to discuss the treatment landscape and management of patients with ALK-positive NSCLC. This article summarizes key data about ALK-positive NSCLC as well as insights from stakeholder discussions regarding this topic.

Related Videos
Benjamin P. Levy, MD
Dr Girard on De Novo and Acquired Resistance Alterations in HER2-Altered NSCLC
Sandip P. Patel, MD
Alec Watson, MD
Balazs Halmos, MD
Balazs Halmos, MD
Suresh Senan, MRCP, FRCR, PhD, full professor, treatment and quality of life, full professor, cancer biology and immunology, full professor, radiation oncology, professor, clinical experimental radiotherapy, Amsterdam University Medical Centers
Alison Schram, MD
Mary B. Beasley, MD, discusses molecular testing challenges in non–small cell lung cancer and pancreatic cancer.
Related Content
NSCLC | © catalin | stock.adobe.com
January 14th 2025

Savolitinib Earns Full Approval in China for Locally Advanced/Metastatic MET Exon 14+ NSCLC

MedNews Week
December 12th 2024

Delve Into Data With Amivantamab Plus Lazertinib in EGFR-Mutated NSCLC: With Chandler Park, MD; and Stephen Liu, MD

The OncFive: Top 5 Oncology Articles of the Week
January 11th 2025

The OncFive: Top Oncology Articles of the Week of 1/5

How to Apply Research Developments in ALK-Positive NSCLC: With Chandler Park, MD, and Tejas Patil, MD
October 16th 2024

How to Apply Research Developments in ALK-Positive NSCLC: With Chandler Park, MD, and Tejas Patil, MD

FDA
January 10th 2025

BBO-8520 Receives FDA Fast Track Designation in KRAS G12C–Mutated Metastatic NSCLC

catalin – stock.adobe.com
January 7th 2025

Sunvozertinib Under FDA Priority Review for NSCLC With EGFR Exon 20 Insertion Mutations